Gilead to buy German biotech Tubulis for up to $5B to bolster cancer drug pipeline

What's the deal? California-based Gilead SciencesDealroom has a profile for this one. Try Dealroom → has agreed to acquire Munich-based biotech Tubulis GmbH for $3.15 billion in upfront cash, with up to $1.85 billion more in contingent milestone payments — bringing the potential total to $5 billion.

The transaction is expected to close in the second quarter of 2026, financed through a combination of cash on hand and senior unsecured notes. Tubulis will operate as a dedicated research organisation within Gilead after closing, with its Munich site serving as a hub for antibody-drug conjugate (ADC) innovation.

Founded by Dominik SchumacherDealroom has a profile for this one. Try Dealroom →, Tubulis is a clinical-stage biotech developing next-generation ADCs — cancer drugs that attach a toxic payload to an antibody designed to seek out tumour cells, delivering the treatment with greater precision than conventional chemotherapy.

Its lead drug, TUB-040, is in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer. A second programme, TUB-030, has shown early clinical promise across multiple solid tumour types.

Gilead has had a collaboration agreement with Tubulis since 2024, giving it significant insight into the company's technology ahead of the acquisition.

Why now? ADCs have emerged as one of the hottest areas in cancer drug development, with several approved products generating billions in annual sales and a wave of pharma M&A targeting the space. Gilead already markets the ADC Trodelvy and has been building its oncology pipeline through acquisitions.

The Tubulis deal follows Gilead's recent agreements to acquire Arcellx and Ouro Medicines, underscoring a push to diversify beyond its HIV franchise as that business matures.

What could go wrong? TUB-040 is in mid-stage clinical development, meaning Gilead is paying $3.15 billion upfront for a drug that has yet to prove efficacy in a pivotal trial. Clinical-stage oncology assets carry significant failure risk; many drugs that show early promise do not survive later-stage testing.

The ADC space is also becoming crowded, with AstraZenecaDealroom has a profile for this one. Try Dealroom →, PfizerDealroom has a profile for this one. Try Dealroom →, and a wave of biotechs all investing heavily in competing programmes.

The signal: Gilead's acquisition of Tubulis is the latest in a series of large biopharma deals chasing ADC technology — a class of drugs that has gone from niche to mainstream in just a few years. The combination of antibody targeting precision and chemotherapy potency has made ADCs one of the most commercially successful innovation cycles in oncology since immunotherapy.

For Gilead, the Munich acquisition also signals a strategic commitment to European oncology innovation and a willingness to pay a premium to secure platform technology before competitors can.

Sources:
Tubulis
Gilead Sciences
Business Wire
EQT Group
Fierce Biotech
Reuters
Bloomberg
The Wall Street Journal

Image source:
Tubulis

J.V.